Fig. 2
From: Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV
Aprepitant plasma and CSF concentrations in non-human primates. a Plasma aprepitant concentrations measured in rhesus monkeys (n = 3/group) following daily oral doses of 80 mg (square) or 125 mg (triangle). Data reflects mean aprepitant plasma concentrations on dense sampling days (1, 7 and 14) + SD. b Plasma (Cp) and CSF steady-state trough concentrations presented as box-n-whisker plots